Alemtuzumab demonstrates durable reduction of MRI activity over 5 years in CARE-MS II with most patients free from treatment for 4 years

Authors
Category Primary study
ConferenceMultiple Sclerosis
Year 2015
This article has no abstract
Epistemonikos ID: 752c102f57225a458b6008bb912aca5278edabe3
First added on: Apr 30, 2026